Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227402 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 904
- Enrollment target
NCT07227402: Recruiting Phase 3 study, sponsored by Merck Sharp & Dohme.
NCT07227402 is a Phase 3 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 904 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227402, a Phase 3 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 904 participants
- Enrollment target
Study Summary
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Primary Outcome
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD will be assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded
Interventions
- DRUG Belzutifan
- DRUG Zanzalintinib
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 904 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2032-02-27 |
| Phase | Phase 3 |
What NCT07227402 shows while recruiting
NCT07227402 is an interventional study that assigns participants to a tested intervention. The registered 904 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Belzutifan is the first listed.
NCT07227402 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07227402 about?
NCT07227402 is a clinical study titled "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)". Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. ...
What is the current status of trial NCT07227402?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 904 participants. The study started on 2025-11-26. Estimated completion is 2032-02-27.
What interventions are being tested in trial NCT07227402?
The interventions under investigation include: Belzutifan (DRUG), Zanzalintinib (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT07227402?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07227402's enrollment target sits among peer trials
904 348th of 2000 higher than 1,653 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI